ReviewCanadian family physician Medecin de famille canadien2025
Approach to steatotic liver disease in the office: Diagnosis, management, and proposed nomenclature.
Review in Canadian family physician Medecin de famille canadien, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Response.Canadian family physician Medecin de famille canadien · 2025Article
- Clinical prudence urged in testing for steatotic liver disease.Canadian family physician Medecin de famille canadien · 2025Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo provide an update on the most recent developments regarding diagnosis and outcomes of steatotic liver disease (SLD), review new nomenclature applied to SLD, and provide an approach to the diagnosis and management of SLD. SOURCES OF INFORMATION: Individual articles published mainly in the past 2 years, found using PubMed and Google Scholar. MAIN MESSAGE: Steatotic liver disease is one of the most common diseases encountered in general practice. This condition is an important biological marker for metabolic syndrome. Diagnosis relies on noninvasive tests. Known complications of metabolic syndrome and advanced liver disease are often present at the time of diagnosis. Courses of action should include assessment of cardiometabolic risk factors and progressive liver dysfunction. Subtle differences are present among patients diagnosed with SLD. Practitioners should be aware of a flux in terminology of SLD. Management of SLD can be guided using a simple algorithm.
conclusionThere is a need for evaluation of the SLD epidemic and its systemic nature, along with associated independent risk factors of cardiovascular disease as well as metabolic conditions such as dyslipidemia, hypertension, and type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.